Big news: The @AmericanCancer Society Journals YouTube channel is now live! 📺 Watch author summaries, CancerSpeak podcast episodes, Editor Spotlights, and more. New videos added regularly. Subscribe: https://t.co/T1y0pmJLFm @OncoAlert @RamalingamMD

The #ASH25 Satellite Symposia are underway 📚 Join Editorial Advisory Board members @DrHKantarjian & Elias Jabbour as they cover the latest advances in ALL management across the patient spectrum. Their recent review offers broader context: https://t.co/5bmnV3eZDP @OncoAlert

$BABA Two pro tells from the weekly: rapid reclaim above the short MAs and steeper higher-lows vs 2022–24. That’s demand pressing, not defending. Disclosure: Long $BABX Watch:

Satellite Symposia are coming up at #ASH25 🌤️ Editorial Advisory Board member Dr. Amir Fathi contributes to the “Consensus or Controversy?” AML session. For a patient-centered lens, see his work on PTSD symptoms during intensive AML therapy: https://t.co/Nyq3gOwqLl @OncoAlert

Good morning from #ASH25 🌅 Editorial Advisory Board member @NicholasShortMD joins the Satellite Symposium “Moving Forward in B-ALL,” exploring modern bispecific antibody approaches. For more on emerging ALL therapies, revisit his review: https://t.co/FoW12k6NK5 @OncoAlert

Our latest CancerScope covers results of the APOLLO trial, which evaluated patients with high-risk acute promyelocytic leukemia treated with the combination of ATRA–ATO in comparison with standard ATRA plus anthracycline-based chemotherapy. https://t.co/usGIwvuuyp @OncoAlert

There was no overall survival advantage to adding venetoclax to bortezomib & dexamethasone for patients with relapsed or refractory #MultipleMyeloma according to results of the phase 3 BELLINI trial. CANCER Section Editor @AjayNookaMD comments: https://t.co/fK08q4m7Ul @OncoAlert

"Community-level work is critical for clinical trial participation." - Dr. Akinyemi Ojesina Listen to a recent episode of CancerSpeak to hear how patient navigators & community champions can encourage more diverse & inclusive clinical trials: https://t.co/4oMLoKTkbc @OncoAlert

New in CancerScope | Two recent studies explored areas of possible therapy de-escalation for women diagnosed with breast cancer. CANCER Deputy Editor and Breast Disease Section Editor @oreganruth is among the experts who weigh in: https://t.co/XDD16LJCOk @OncoAlert

New & available #OpenAccess | Chemoradiotherapy significantly improves survival in IDH wild-type/telomerase reverse transcriptase promoter mutation grade 2 to 3 gliomas with favorable safety. https://t.co/PkbidmEKHm @OncoAlert #BrainCancer

In this large cohort w/ extended follow-up, subtotal resection patients exhibited a 2nd recurrence peak at 7-10 years postoperatively. Adjuvant Gamma Knife radiosurgery showed long-term benefit, supporting its selective use & surveillance beyond 10 years. https://t.co/vFyYuBIwgQ

💻 Can virtual networking & women-focused organizations close gender gaps in academic medicine—or do they introduce new challenges? Dr @JenniferGrandis weighs in with host @oreganruth on a recent episode of CancerSpeak. https://t.co/vW9TdyKER8 @OncoAlert @JacquiCallander

New & available #OpenAccess | Self-reported overall well-being and physical function were moderately correlated with common symptoms, offered discriminant and face validity, and were associated with clinical outcomes. https://t.co/NPjnxSxl4M @OncoAlert

A new editorial from @fredhutch investigators Drs. Benjamin Anderson & Christopher Li comments on the recent lobular breast cancer statistics report from @AmericanCancer researchers. 🔗 Editorial: https://t.co/DDD5HfYvLa 🔗 ACS report: https://t.co/H7LKqcRcJ7 @OncoAlert

🧵 Tweetorial: 1/ MRI is now central to prostate cancer workup — but does what we see on MRI predict outcomes? In a national cohort of 2,275 veterans, we found that MRI-detected EPE is common & highly prognostic.

The number of cancer survivors is rising, and so is the need for focused research. Explore the @AmericanCancer Journals' virtual collection on survivorship research, including statistics, care planning, and long-term outcomes. 🔗 https://t.co/vKvgufrZ8M @OncoAlert

"Expanding eligibility, mitigating bias, and supporting patients throughout the research process are not just strategies, they are imperatives for justice in cancer care." Read the editorial by Nupur Mittal MD of @RushMedical: https://t.co/G3tYDBZtdK @OncoAlert

Position Statement from @auroragrutman (@HopkinsMedicine) and Christian P. Pavlovich MD (@brady_urology) | The One Big Beautiful Bill Act and the future of prostate cancer care https://t.co/l7jKlKLrz2 @OncoAlert #PCSM

New commentary by @AydinAMurat, @MaartenAlbersen, and @SpiessPhilippe | A call for raising public awareness and improving outcomes of penile cancer https://t.co/9sS6astNXA @OncoAlert

MRI-detected extraprostatic extension, including major capsule abutment, is common in localized #ProstateCancer (PC) and independently prognostic. MRI findings should be considered in the next iteration of PC staging. https://t.co/LDJLzR9sok @OncoAlert #RadOnc #PCSM

A new study published in @JournalCancer reveals that certain social determinants of health have significant effects on rural–urban disparities in #ColorectalCancer mortality rates. The findings are covered by @medical_xpress: https://t.co/tkbJcMJLrP @ACS_Research

Now available: Findings from a retrospective analysis of 82 patients with thymic MALT lymphoma diagnosed at multiple medical centers in China between 2011-2024. Authors conclude patients with thymic MALT lymphoma have an excellent prognosis. https://t.co/kmPryeiHki @OncoAlert